ipamorelin dosage Cycle Guide: Optimal Dosage, Timing, and Best Peptide Stack CJC-1295/Ipamorelin Dosage: Dosing & Cycle

Rubin, B

PMID: 19289567 Wideman L, Weltman JY, Patrie JT, Bowers CY, Shah N, Story S, et al

The antioxidative property of phytic acid and its potentional anticancerogenic activities are briefly surveyed

The findings established Ipamorelin's defining characteristic: Growth hormone Ipamorelin produced dose-dependent GH release comparable to GHRP-6 Cortisol No significant cortisol elevation was observed with Ipamorelin, while GHRP-2 and GHRP-6 produced measurable cortisol increases Prolactin No significant prolactin elevation at GH-effective concentrations ACTH No significant ACTH stimulation, contrasting with the adrenocorticotropic effects of other GHRPs GHRP Selectivity Comparison (Preclinical Data) Compound GH Release Cortisol Effect Prolactin Effect ACTH Effect Ipamorelin Dose-dependent Minimal / none Minimal / none Minimal / none GHRP-2 Dose-dependent Moderate increase Moderate increase Moderate increase GHRP-6 Dose-dependent Moderate increase Moderate increase Moderate increase Hexarelin Strong Significant increase Significant increase Significant increase Data adapted from Raun et al

HO-1 degrades heme through a series of catabolic steps that yield products including biliverdin, carbon monoxide (CO) and free iron (Gozzelino et al., 2010)